Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2011

View Archived Issues

Novel inhibitors of glycoprotein-mediated viral entry reported by Microbiotix

Novel adenosine A2A receptor antagonists patented

Ongoing phase I/II trial suggests safety of CDCA1-A24-56 vaccine in patients with CRPC

New vaccine targeting morphine dependency shows promise in rats

Merck & Co. patents novel glucocorticoid receptor modulators

Scientists at Vantia prepare new kallikrein-1 inhibitors

Italian scientists prepare novel histone deacetylase inhibitors for cancer

FDA approves Abbott's Xience nano stent for coronary artery disease in small vessels

Radius Health provides update on BA-058 formulations for osteoporosis

MGMTP140K gene-modified cells are safe and confer chemoprotection in phase I/II glioblastoma trial

New selective glucocorticoid receptor antagonists prevent olanzapine-induced weight gain in vivo

Monoclonal antibody against beta-amyloid reduces symptoms of AMD in vivo

NeuroSearch to conduct phase III confirmatory trial of Huntexil

Evotec and PsychoGenics form strategic alliance for CNS drug discovery solutions

EMD Serono launches Cyanokit in Canada for cyanide poisoning

ViroPharma begins phase II trial of VP-20621 for prevention of CDI recurrence

Johnson & Johnson designs new delta opioid receptor ligands

KemPharm reports results from phase I KP-201 trial

Metabolex begins phase II trial of arhalofenate in patients with gout

Daiichi Sankyo launches vaccine for prevention of measles and rubella in Japan

Orion patents new androgen receptor modulators for prostate cancer

Advantagene and FDA agree on SPA for phase III ProstAtak trial

Primary endpoints met in Vivus' phase III trial of avanafil for ED after radical prostatectomy

Proteostasis Therapeutics and Elan join to discover treatments for neurodegenerative disorders

Achillion's ACH-2684 advances to first-in-human study in chronic hepatitis C

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...